Antisense Therapeutics Limited
ASX:ANP ISIN:AU000000ANP4
The development of novel antisense pharmaceuticals for commercially important human conditions.
News
ANTISENSE THERAPEUTICS LIMITED (ASX: ANP) - Commencement of Phase IIa Multiple Sclerosis Trial - Mr Mark Diamond, CEO; Boardroomradio is pleased to announce that ANTISENSE THERAPEUTICS LIMITED (ASX: ANP) has published an audio file.
###
830 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 2) (Last 30 Days: 19) (Since Published: 830)
